Loading clinical trials...
Loading clinical trials...
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Conditions
Interventions
GSK1278863
rhEPO
Locations
123
United States
GSK Investigational Site
Peoria, Arizona, United States
GSK Investigational Site
Azusa, California, United States
GSK Investigational Site
La Mesa, California, United States
GSK Investigational Site
Laguna Hills, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Los Angeles, California, United States
Start Date
October 31, 2013
Primary Completion Date
May 1, 2015
Completion Date
June 15, 2015
Last Updated
October 12, 2018
NCT06884280
NCT07082205
NCT06601712
NCT05251493
NCT07340450
NCT05681871
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions